Company Overview
Company Type: Public Company
Website: www.gilead.com
Number of Employees: 17,000
Ticker: GILD (NasdaqGS)
Year Founded: 1987


Business Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Financial Information (Currency: CAD, in mm) 
Total Revenue
37,616.0
Market Capitalization
127,933.4
TEV/Total Revenue
4.0x
EBITDA
16,710.3
Total Enterprise Value
150,943.7
TEV/EBITDA
8.9x
EBIT
13,449.0
Cash & ST Invst.
9,750.9
P/Diluted EPS Before Extra
17.2x
Net Income
7,533.6
Total Debt
34,681.7
Price/Tang BV
NM
Capital Expenditure
(805.0)
Total Assets
85,635.5
Total Debt/EBITDA
2.0x
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates & Guidance Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Guidance Current FQ
Current FY
Guidance Current FY
NTM
EPS Normalized
2.63
-
9.05
8.86 - 9.34
10.41
Revenue (mm)
9,354.10
-
36,925.09
-
37,422.23
EBITDA (mm)
5,087.72
-
17,795.63
-
18,749.59

Forward Multiples (Current FY)

Price/Earnings
11.34x
TEV/REV
4.09x
TEV/EBITDA
8.48x
PEG
2.56x
P/BV
4.07x

Non-Periodic Estimates

Recommendation
Outperform (2.13)
Target Price
125.15
Potential Upside
21.89%
LT Growth (%)
4.43%


Key Professionals
Name
Title
O'Day, Daniel P. 
Chairman & CEO
Dickinson, Andrew D.
Executive VP & CFO
Patterson, Sandra 
Senior VP, Corporate Controller & Principal Accounting Officer
Ross, Jacquie 
Vice President of Investor Relations
Telman, Deborah H.
Executive VP of Corporate Affairs, General Counsel & Corporate Secretary
Mehra, Jyoti K.
Executive Vice President of Human Resources
Dorling, Janet 
Senior Vice President of Intercontinental Region & Global Patient Solutions
Ertl, Rudolf 
Senior Vice President of Commercial Operations of Australia, Canada, Europe
Fine, Bernard 
VP of Oncology & Franchise Head of Early Development
Grossman, William J.
Senior Vice President & Therapeutic Area Head of Gilead Oncology
Higgins, Linda Slanec
Senior Vice President of Research, Innovation & Portfolio
Ma, Stacey 
Executive VP of Pharmaceutical Development & Manufacturing

Key Board Members
Name
Title
Colon, Grace E.
Chairman of the Board
O'Day, Daniel P. 
Chairman & CEO
Huff, Joel R.
Chairperson of Scientific Advisory Board
Kramer, Kelly A.
Independent Director
Lofton, Kevin E.
Lead Independent Director
Welters, Anthony 
Independent Director
Afdhal, Nezam H.
Member of Scientific Advisory Board
Anderson, Kenneth C.
Member of the Scientific Advisory Board
Barton, Jacqueline K.
Independent Director
Berg, Paul 
Member of Scientific Advisory Board
Bluestone, Jeffrey A.
Independent Director
Chisari, Francis V.
Member of the Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
333 Lakeside Drive | Foster City, CA | 94404 | United States
Phone: 650 574 3000   Fax: 650 522 5853

Current and Pending Investors
Capital Research Global Investors, Capital World Investors, Elo Mutual Pension Insurance Company, Friends Fiduciary Corporation, Ilmarinen Mutual Pension Insurance Company, Keskinäinen työeläkevakuutusyhtiö Varma, Kleiner Perkins Caufield & Byers, Maryknoll Sisters of St. Dominic, Inc., Medicxi Ventures (UK) LLP, Mercy Investment Services, Oxford Science Enterprises, PRIVATE EQUITY, Rosinger Anlagentechnik GmbH & Co KG, Samsara BioCapital LLC, Shareholder Association for Research & Education, T. Rowe Price Associates, Inc., Tekla Capital Management LLC, Temasek Holdings (Private) Limited, The Adrian Dominican Sisters, Warburg Pincus LLC

Prior Investors
3i Group plc (LSE:III), Abingworth LLP, BB Biotech AG (SWX:BION), Bellevue Asset Management AG, Bio*One Capital Pte Ltd, Biotechnology Venture Fund, Concord Ventures, EDBI Pte Ltd, HBM Healthcare Investments AG (SWX:HBMN), HBM Partners Ltd., Health Care & Biotechnology Venture Fund, International Biotechnology Trust plc (LSE:IBT), J.H. Whitney Capital Partners, LLC, John Hancock Investment Management Distributors LLC, Lumira Ventures, Menlo Ventures Management, L.P. (Henry Montgomery), Merrill, Pickard, Anderson & Eyre, NB Capital ApS, SIG Holdings, Inc., Singapore Bio-Innovations Pte Ltd., SV Health Investors, LLC, Vista Technology Group, Ltd., The, VR Adviser, LLC, William Blair Capital Partners, L.L.C., William Blair Venture Partners III, L.P.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 102.39
Market Cap (mm)
127,933.4
Open
 102.58
Shares Out. (mm)
1,246.0
Previous Close
 102.67
Float %
99.9%
Change on Day
(0.29)
Shares Sold Short (mm)
18.3
Change % on Day
(0.3)%
Dividend Yield %
4.0%
Day High/Low
 103.07/ 101.86
Diluted EPS Excl. Extra Items
5.98
52 wk High/Low
 123.28/ 87.87
P/Diluted EPS Before Extra
17.21x
Volume (mm)
2.25
Avg 3M Dly Vlm (mm)
5.46
Beta 5Y
0.35


 
Delayed Quote** | Last Updated on Oct-05-2023 03:34 PM (GMT-5)
NasdaqGS:GILD - Common Stock


Index Membership
S&P 500;S&P 500 Health Care (Sector);S&P 100;S&P Composite 1500;S&P 500 Growth;S&P Global 1200;S&P 500 - Biotechnology (Sub Ind);S&P 500 - Biotechnology (Industry);S&P 500 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P 500 Equal Weighted;S&P 900 Pure Growth;S&P 900 Growth;S&P TMI Index;S&P Global 1200 Health Care Index;S&P 900;S&P 500 Pure Growth;S&P Biotechnology Select Industry Index;S&P Composite 1500 - Biotechnology (Industry);S&P Composite 1500 - Biotechnology (Sub Ind);S&P Composite 1500 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Composite 1500 Health Care (Sector);S&P Composite 1500 Growth;S&P Composite 1500 Pure Growth;S&P 500 EQUAL WEIGHTED Health Care (Sector);S&P 500 Ex-Financials, Real Estate, Utilities and Transportation Index;S&P 500 Dividend Index;S&P Americas BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas BMI Value Index;S&P Americas BMI Index;S&P Americas BMI Health Care (Sector) Index;S&P Americas LargeMidCap Health Care (Sector) Index;S&P Developed BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas LargeMidCap Index;S&P Americas LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Americas LargeMidCap Value Index;S&P Americas Over USD5 Billion Index;S&P Developed Ex-Asia-Pacific LargeMidCap Value Index;S&P Developed BMI Value Index;S&P Developed Ex-Asia-Pacific BMI Value Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Europe BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Europe LargeMidCap Index;S&P DM Ex-Europe LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed BMI Index;S&P Developed Ex-Australia BMI Index;S&P Developed Ex-Australia LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Index;S&P DM Ex-Asia-Pacific BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Asia-Pacific BMI Value Index;S&P Developed Ex-Australia LargeMidCap Index;S&P Developed Ex-Australia LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Canada BMI Index;S&P Developed Ex-Canada BMI Health Care (Sector) Index;S&P Developed Ex-Canada BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Index;S&P Developed Ex-Switzerland LargeMidCap Health Care (Sector) Index;S&P Developed Ex-U.K. BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. LargeMidCap Health Care (Sector) Index;S&P DM Ex-U.K. LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Eurozone BMI Index;S&P Developed Ex-Eurozone LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Eurozone LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Eurozone LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Japan BMI Index;S&P Developed Ex-Japan BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Index;S&P Developed Ex-Asia-Pacific LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Australia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia LargeMidCap Value Index;S&P Developed Ex-Switzerland BMI Health Care (Sector) Index;S&P Developed Ex-Switzerland LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia BMI Health Care (Sector) Index;S&P DM Ex-Canada LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland LargeMidCap Index;S&P Developed Ex-U.K. BMI Health Care (Sector) Index;S&P Developed Ex-Europe LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Europe LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Value Health Care (Sector) Index;S&P Developed Ex-Eurozone LargeMidCap Value Index;S&P Developed Ex-Eurozone Over USD5 Billion Index;S&P Developed Ex-Switzerland LargeMidCap Value Index;S&P Developed Ex-Canada BMI Value Health Care (Sector) Index;S&P Developed Ex-Europe BMI Index;S&P Developed Ex-U.K. BMI Value Health Care (Sector) Index;S&P Developed Ex-U.K. LargeMidCap Index;S&P Developed Ex-U.K. Over USD5 Billion Index;S&P Developed Ex-U.K. BMI Value Index;S&P Developed Ex-U.K. LargeMidCap Value Index;S&P Developed BMI Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific Over USD5 Billion Index;S&P Developed Ex-Australia BMI Value Health Care (Sector) Index;S&P Developed Ex-Europe Over USD5 Billion Index;S&P Developed Ex-Japan BMI Value Health Care (Sector) Index;S&P Developed Ex-Japan LargeMidCap Index;S&P Developed Ex-Australia Over USD5 Billion Index;S&P Developed Ex-Canada LargeMidCap Index;S&P Developed Ex-Canada LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Canada Over USD5 Billion Index;S&P Developed Over USD5 Billion Index;S&P Global BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia BMI Health Care (Sector) Index;S&P Global Ex-Pan Asia BMI Value Index;S&P Developed Ex-Europe BMI Value Index;S&P Developed Ex-Eurozone BMI Value Index;S&P Developed Ex-Eurozone LargeMidCap Index;S&P Developed Ex-Japan LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Japan LargeMidCap Value Index;S&P DM Ex-Switzerland BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland BMI Value Index;S&P Developed Ex-Switzerland LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed LargeMidCap Index;S&P Developed LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Switzerland Over USD5 Billion Index;S&P Developed Ex-Australia BMI Value Index;S&P Developed Ex-Canada BMI Value Index;S&P Developed Ex-Europe BMI Health Care (Sector) Index;S&P Developed Ex-Europe BMI Value Health Care (Sector) Index;S&P Developed Ex-Eurozone BMI Health Care (Sector) Index;S&P DM Ex-Japan LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Japan Over USD5 Billion Index;S&P Global Ex-Japan Over USD5 Billion Index;S&P Global Ex-Pan Asia BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-U.K. BMI Index;S&P Global Ex-Japan BMI Value Index;S&P Global BMI Index;S&P Global Ex-Japan BMI Health Care (Sector) Index;S&P Global Ex-Japan LargeMidCap Index;S&P Global Ex-Japan LargeMidCap Value Index;S&P Global Ex-Pan Asia LargeMidCap Value Index;S&P Global Ex-Pan Asia Over USD5 Billion Index;S&P North America BMI Value Health Care (Sector) Index;S&P North America LargeMidCap Value Health Care (Sector) Index;S&P North America Over USD5 Billion Index;S&P Global Ex-Pan Asia LargeMidCap Health Care (Sector) Index;S&P Global Over USD5 Billion Index;S&P North America BMI Index;S&P North America LargeMidCap Index;S&P North America LargeMidCap Value Index;S&P Global Ex-Japan LargeMidCap Health Care (Sector) Index;S&P Global Ex-Japan LargeMidCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P United States BMI Index;S&P Global LargeMidCap Health Care (Sector) Index;S&P United States BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P North America BMI Value Index;S&P United States BMI Health Care (Sector) Index;S&P United States LargeMidCap Value Health Care (Sector) Index;S&P United States BMI Value Health Care (Sector) Index;S&P United States LargeMidCap Health Care (Sector) Index;S&P United States Over USD5 Billion Index;S&P Global Ex-Japan BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global Ex-Pan Asia BMI Index;S&P Global Ex-Pan Asia LargeMidCap Index;S&P Global Ex-Pan Asia LargeMidCap Pharmaceuticals, Biotech & Life Sciences (Industry Group) Index;S&P Global LargeMidCap Index;S&P Global LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Global LargeMidCap Value Index;S&P North America BMI Health Care (Sector) Index;S&P North America LargeMidCap Health Care (Sector) Index;S&P North America LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P United States BMI Value Index;S&P Developed BMI Value Health Care (Sector) Index;S&P Developed Ex-Asia-Pacific BMI Health Care (Sector) Index;S&P Developed Ex-Australia LargeMidCap Pharma., biotech. & Life Sci. (Industry Group) Index;S&P Developed Ex-Canada LargeMidCap Health Care (Sector) Index;S&P Developed Ex-Canada LargeMidCap Value Index;S&P Developed Ex-Europe LargeMidCap Value Index;S&P Developed Ex-Japan BMI Value Index;S&P Developed Ex-Japan LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Switzerland BMI Value Health Care (Sector) Index;S&P Developed Ex-U.K. LargeMidCap Value Health Care (Sector) Index;S&P Developed LargeMidCap Health Care (Sector) Index;S&P Developed LargeMidCap Value Index;S&P Developed LargeMidCap Value Health Care (Sector) Index;S&P Global BMI Health Care (Sector) Index;S&P Global BMI Value Index;S&P Global Ex-Japan BMI Index;S&P United States LargeMidCap Index;S&P United States LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P United States LargeMidCap Value Index;S&P 100 Equal Weight Price Return (USD) Index;S&P Developed Ex-Eurozone BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Asia Pacific BMI Value Pharm, Biotech & Life Sciences (Industry Group) Index;S&P Developed Ex-Australia BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Switzerland BMI Value Pharm, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-UK BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Europe BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Canada BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P United States BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P North America BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)  Index;S&P Developed Ex-Japan BMI Value Pharm, Biotechnology & Life Sciences (Industry Group)  Index;S&P TMI Health Care;S&P Developed Ex-Israel BMI Index;S&P Developed Ex-Israel BMI Health Care (Sector) Index;S&P Developed Ex-Israel BMI Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel BMI Value Index;S&P Developed Ex-Israel BMI Value Health Care (Sector) Index;S&P Developed Ex-Israel LargeMidCap Index;S&P Developed Ex-Israel LargeMidCap Health Care (Sector) Index;S&P DM Ex-Israel LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index;S&P Developed Ex-Israel LargeMidCap Value Index;S&P Developed Ex-Israel LargeMidCap Value Health Care (Sector) Index;S&P Developed Ex-Israel Over USD5 Billion Index;S&P Global 1200 - Biotechnology (Industry);S&P Global 1200 - Biotechnology (Sub Ind);S&P Global 1200 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-Australia BMI Index;S&P Global Ex-Europe BMI Index;S&P Global Ex-United Kingdom BMI Index;S&P Developed Ex-Continental Europe BMI Index;S&P Developed Ex-Japan, Ex-South Korea BMI Index;S&P DM Ex. Japan LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-Australia LargeMidCap;S&P Developed Ex-Japan & South Korea LargeMidCap;S&P 100 Health Care;S&P DM Ex-Canada LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subsecto;S&P Developed Ex-Asia-Pacific LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subs;S&P Developed Ex-Australia LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subsect;S&P Developed Ex-Israel BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Subse;S&P DM Ex-Europe LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-U.K. LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P DM Ex-Israel LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P North America LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P United States LargeMidCap Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Global Ex-Australia & New Zealand LargeMidCap;S&P Global Ex-China A BMI;S&P Global Ex-China A LargeMidCap;S&P Developed Ex-Korea BMI;S&P 500 Low Volatility High Dividend Index;S&P Global Ex-Japan & China A LargeMidCap;S&P Developed Ex-Korea LargeMidCap;S&P Developed BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific BMI Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Canada BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Australia BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Europe LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Eurozone BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Israel LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Asia Pacific LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-UK LargeMidCap Val Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P United States BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Canada LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Japan LargeMidCap Val Pharma, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Switzerland BMI Val Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P North America BMI Value Pharmaceuticals, Biotechnology & Life Sciences (Industry Group);S&P Developed Ex-Korea BMI Value;S&P Developed Ex-Korea LargeMidCap Value;S&P Global 1200 Ex-Canada;S&P Developed Ex-Korea LargeMidCap Health Care (Sector) Index;"S&P Developed Ex-Korea LargeMidCap Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
MiroBio Ltd
MiroBio Ltd develops and manufactures antibody modulators of immune cell receptors for auto-immune diseases. The company also develops antibodies and immune cell signals. The company offers research and development; and experimental development services for biotechnology industry. The company was incorporated in 2018 and is based in Oxford, United Kingdom. As of September 20, 2022, MiroBio Ltd operates as a subsidiary of Gilead Sciences, Inc.

Europe
Pharmaceuticals
-
-
-
HOOKIPA Pharma Inc. (NasdaqGS:HOOK) (Pending)
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company’s preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

United States and Canada
Biotechnology
16.00
191.00
4.00
MYR GmbH
MYR GmbH operates as a biotechnology company that engages in the development and commercialization of therapeutics for the treatment of chronic hepatitis B (HBV) and D (HDV) infections. It offers Bulevirtide, an entry inhibitor for the treatment of chronic HBV and HDV, as well as opens-up new possibilities for the treatment of a variety of inflammatory and metabolic diseases. The company was founded in 2011 and is based in Bad Homburg, Germany. As of March 4, 2021, MYR GmbH operates as a subsidiary of Gilead Sciences, Inc.

Europe
Biotechnology
-
-
-
Immunomedics, Inc.
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products to treat cancer. The company develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. It focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for the treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. The company has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was incorporated in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.

United States and Canada
Biotechnology
20.00
1,077.00
10.00
Forty Seven, Inc.
Forty Seven, Inc., a clinical-stage immuno-oncology company, focuses on developing novel therapies to activate macrophages for the treatment of cancer. It offers magrolimab, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. The company has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin’s lymphoma; and collaboration with Acerta Pharma to evaluate novel immuno-oncology triple combination in diffuse large B-Cell Lymphoma. Forty Seven, Inc. was formerly known as CD47 Sciences, Inc. The company was incorporated in 2014 and is headquartered in Foster City, California. It has locations in North America, South America, Asia, the Middle East, Africa, Australia, and Europe. Forty Seven, Inc. operates as a subsidiary of Gilead Sciences, Inc.

United States and Canada
Biotechnology
16.00
344.00
2.00
Kite Pharma, Inc.
Kite Pharma, Inc. develops novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. In addition, it engages in developing T cell receptor-based therapies that target self-antigens, viral antigens, and neo-antigens. The company was incorporated in 2009 and is based in Santa Monica, California with additional locations in Santa Monica, El Segundo, Oceanside, Emeryville, California; Frederick, Maryland; United Kingdom; and the Netherlands. As of October 2, 2017, Kite Pharma, Inc. operates as a subsidiary of Gilead Sciences, Inc.

United States and Canada
Biotechnology
32.00
907.00
0.00
Nimbus Apollo, Inc.
As of April 4, 2016, Nimbus Apollo, Inc. was acquired by Gilead Sciences, Inc. Nimbus Apollo, Inc. research and develops drugs that treats non-alcoholic steatohepatitis. The company was incorporated in 2010 and is based in Cambridge, Massachusetts. Nimbus Apollo, Inc. was formerly a subsidiary of Nimbus Therapeutics, Inc.

United States and Canada
Life Sciences Tools and Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-7-2023
Sep-7-2023
Public Offering
Target
Gilead Sciences, Inc. (NasdaqGS:GILD)


998.38
Sep-7-2023
Sep-7-2023
Public Offering
Target
Gilead Sciences, Inc. (NasdaqGS:GILD)


997.75
Sep-7-2023
-
Public Offering
Target
Gilead Sciences, Inc. (NasdaqGS:GILD)


-
Aug-28-2023
Sep-06-2023
Private Placement
Buyer
Tentarix Biotherapeutics, LP
Versant Venture Management, LLC,Samsara BioCapital LLC,Amplitude Ventures,Gilead Sciences, Inc. (NasdaqGS:GILD)

35.00
Aug-7-2023
-
Shelf Registration
Target
Gilead Sciences, Inc. (NasdaqGS:GILD)


1,967.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-21-2023
Company Conference Presentations
Gilead Sciences, Inc. Presents at IPF Summit, Sep-21-2023 01:00 PM
Sep-20-2023
Company Conference Presentations
Gilead Sciences, Inc. Presents at Mobile Tech in Clinical Trials 2023, Sep-20-2023
Sep-20-2023
Company Conference Presentations
Gilead Sciences, Inc. Presents at 13th annual DPHARM: Disruptive Innovations, Sep-20-2023
Sep-19-2023
Product-Related Announcements
Gilead Sciences, Inc. Announces CHMP of EMA Adopts Positive Opinion to Extend Use of Veklury (Remdesivir) to Treat COVID-19 in People with Hepatic Impairment
Sep-18-2023
Product-Related Announcements
Kite, A Gilead Company Announces Car T-Cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

Competitors
Acasti Pharma Inc. (NasdaqCM:ACST), Akzo Nobel N.V. (ENXTAM:AKZA), Alexion Pharmaceuticals, Inc., Alkeus Pharmaceuticals, Inc., Amarin Corporation plc (NasdaqGM:AMRN), Amgen Inc. (NasdaqGS:AMGN), Arkema Inc., Astellas Pharma Inc. (TSE:4503), BASF Corporation, BASF SE (XTRA:BAS), Baxalta Incorporated, Bayer Corporation, Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Boehringer Ingelheim GmbH, Cardax, Inc. (OTCPK:CDXI), Chandra Bhagat Pharma Limited (BSE:542934), Clariant AG (SWX:CLN), Coherus BioSciences, Inc. (NasdaqGM:CHRS), CoTherix, Inc., Croda International Plc (LSE:CRDA), CSL Limited (ASX:CSL), Cullinan Oncology, Inc. (NasdaqGS:CGEM), Daiichi Sankyo Company, Limited (TSE:4568), Diocle S.p.A., Dynavax Technologies Corporation (NasdaqGS:DVAX), Eisai Co., Ltd. (TSE:4523), Eli Lilly and Company (NYSE:LLY), Eli Lilly and Company Limited, EMD Millipore Corporation, F. Hoffmann-La Roche Ltd, GeneraMedix, Inc., Geron Corporation (NasdaqGS:GERN), Glaxosmithkline Biologicals S.A., Illumina, Inc. (NasdaqGS:ILMN), Insmed Incorporated (NasdaqGS:INSM), ISP Capital Co., Ltd., Janssen Pharmaceuticals, Inc., Janssen R&D Ireland, Janssen Research & Development, LLC, Janssen Therapeutics, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Johnson & Johnson (NYSE:JNJ), Johnson & Johnson LLC, K+S Aktiengesellschaft (XTRA:SDF), Kubota Pharmaceutical Holdings Co., Ltd. (TSE:4596), LANXESS Corporation, LES LABORATOIRES SERVIER, SAS, Matinas BioPharma Holdings, Inc. (NYSEAM:MTNB), Medtronic plc (NYSE:MDT), Merck (Schweiz) AG, Merck Sharp & Dohme LLC, Mitsubishi Tanabe Pharma Corporation, Moderna, Inc. (NasdaqGS:MRNA), Mylan Pharmaceuticals Inc., Novartis International AG, Novo Nordisk A/S (CPSE:NOVO B), Ono Pharmaceutical Co., Ltd. (TSE:4528), Onyx Pharmaceuticals, Inc., Perrigo Company plc (NYSE:PRGO), Pfizer Limited (NSEI:PFIZER), Piramal Enterprises Limited (BSE:500302), Precigen, Inc. (NasdaqGS:PGEN), Rain Oncology Inc. (NasdaqGS:RAIN), Reata Pharmaceuticals, Inc., ReceptoPharm, Inc., Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Rhodia S.A., Sandoz International GmbH, Sanofi Pasteur Inc., Sanofi SA, Solvay SA (ENXTBR:SOLB), Spectrum Pharmaceuticals, Inc., SteadyMed Ltd., Taiho Pharmaceutical Co., Ltd., TaiMed Biologics Inc. (TPEX:4147), Takeda Pharmaceutical Company Limited (TSE:4502), TALi Digital Limited (ASX:TD1), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Theratechnologies Inc. (TSX:TH), Tibotec, Inc. (Acquired), UCB SA (ENXTBR:UCB), VBI Vaccines Inc. (NasdaqCM:VBIV), VIVUS, Inc., Wacker Chemie AG (XTRA:WCH)

M&A Advisors
Barclays Capital Inc., Bear, Stearns & Co. Inc., Blake, Cassels & Graydon LLP, BofA Securities, Inc., Citigroup Global Markets Inc., Cooley LLP, Covington & Burling LLP, Cowen and Company, LLC, Cowen Inc., Davis Polk & Wardwell LLP, Ernst & Young LLP, Flick Gocke Schaumburg, Gibson, Dunn & Crutcher LLP, Goldman Sachs & Co. LLC, Herbert Smith Freehills LLP, J.P. Morgan & Co. Incorporated, J.P. Morgan Securities LLC, Jones Day, Lazard Freres & Co. LLC, Lazard Ltd (NYSE:LAZ), Mayer Brown LLP, McKee Nelson LLP, Merrill Lynch & Co., Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Mishcon De Reya LLP, Mizuho Securities USA LLC, Morgan Stanley & Co. LLC, Morgan, Lewis & Bockius LLP, Richards, Layton & Finger, P.A., Ropes & Gray LLP, Skadden, Arps, Slate, Meagher & Flom LLP, Wilson Sonsini Goodrich & Rosati, P.C.


Advisors
Most Recent Auditor
Ernst & Young LLP
M&A Advisors
Barclays Capital Inc., Bear, Stearns & Co. Inc., Blake, Cassels & Graydon LLP, BofA Securities, Inc., Citigroup Global Markets Inc., Cooley LLP, Covington & Burling LLP, Cowen and Company, LLC, Cowen Inc., Davis Polk & Wardwell LLP, Ernst & Young LLP, Flick Gocke Schaumburg, Gibson, Dunn & Crutcher LLP, Goldman Sachs & Co. LLC, Herbert Smith Freehills LLP, J.P. Morgan & Co. Incorporated, J.P. Morgan Securities LLC, Jones Day, Lazard Freres & Co. LLC, Lazard Ltd (NYSE:LAZ), Mayer Brown LLP, McKee Nelson LLP, Merrill Lynch & Co., Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Mishcon De Reya LLP, Mizuho Securities USA LLC, Morgan Stanley & Co. LLC, Morgan, Lewis & Bockius LLP, Richards, Layton & Finger, P.A., Ropes & Gray LLP, Skadden, Arps, Slate, Meagher & Flom LLP, Wilson Sonsini Goodrich & Rosati, P.C.
Private Placement Advisors
Bank of America Corporation (NYSE:BAC), Barclays PLC (LSE:BARC), Centerview Partners LLC, Covington & Burling LLP, Cowen Inc., Eubelius, Hogan Lovells US LLP, Lazard Group LLC, Lazard Ltd (NYSE:LAZ), Morgan Stanley & Co. LLC, Skadden, Arps, Slate, Meagher & Flom LLP, Venable LLP
Public Offering Advisors
Cooley LLP, Davis Polk & Wardwell LLP, Ernst & Young LLP, J. Wood Capital Advisors LLC, Latham & Watkins LLP, Skadden, Arps, Slate, Meagher & Flom LLP


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:17 AM
GILD
Gilead Sciences Inc 2023_10_05
Reports
16
GlobalData

01:50 AM
GILD
Gilead Sciences Inc (GILD.NASD) - Financial and Strategic SWOT Analysis Review
Reports
797
ValuEngine, Inc.

Oct 02, 2023 04:31 AM
GILD
ValuEngine Rating and Forecast Report for GILD
Reports
11
The Economy Matters

Oct 02, 2023 02:56 AM
GILD
The Economy Matters
Reports
8
CFRA Equity Research
Hardy, Sel
Sep 30, 2023 04:25 PM
GILD
Gilead Sciences, Inc.
Reports
9
New Constructs, LLC

Sep 29, 2023 08:16 PM
GILD
GILD: Forensic Stock Earnings & Valuation
Reports
6
J.P. Morgan
Schott, Christopher Thomas
Sep 28, 2023 04:09 PM
GILD
Gilead Sciences: Readacross from GSK HIV Updates Highlights Meaningful PrEP Growth as well as Long-Acting Treatment Potential
Notes
8
Barclays
Gould, Carter Lewis
Sep 28, 2023 09:43 AM
GILD
Gilead Sciences, Inc.: Obeldesvir Strategy Takes a Hit with BIRCH Update
Fixed Income*
9
GlobalData

Sep 28, 2023 06:19 AM
GILD
Gilead Sciences Inc (GILD.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
767
Zacks Investment Research Inc.

Sep 28, 2023 03:36 AM
GILD
Gilead Sciences, Inc(GILD) Zacks Company Report
Reports
10


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Capital Research and Management Company

139,017,518

11.16

14,008.8

Jun-30-2023


BlackRock, Inc.

126,194,179

10.13

12,716.5

Jun-30-2023


The Vanguard Group, Inc.

113,368,650

9.10

11,424.1

Jun-30-2023


State Street Global Advisors, Inc.

59,317,162

4.76

5,977.4

Jun-30-2023


Dodge & Cox

33,979,757

2.73

3,424.1

Jun-30-2023


Geode Capital Management, LLC

24,212,636

1.94

2,439.9

Jun-30-2023


FMR LLC

18,663,943

1.50

1,880.8

Jun-30-2023


BNY Mellon Asset Management

17,024,374

1.37

1,715.5

Jun-30-2023


Wellington Management Group LLP

16,641,502

1.34

1,677.0

Jun-30-2023


Northern Trust Global Investments

14,418,013

1.16

1,452.9

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Wellington Management Group LLP
16,641,502
12,539,306
Capital Research and Management Company
139,017,518
4,203,321
Van Eck Associates Corporation
3,832,497
1,832,292
State Street Global Advisors, Inc.
59,317,162
1,514,894
Barclays PLC Private Banking & Investment Banking Investment
3,581,338
1,471,782

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Marshall Wace LLP
39,190
(5,035,412)
Renaissance Technologies LLC
7,781,416
(2,802,800)
Federated Hermes, Inc.
3,562,344
(2,049,861)
Citadel Advisors LLC
298,866
(1,952,853)
First Trust Advisors LP
4,045,072
(1,824,781)


S&P Global Ratings Credit Ratings
Debt Type (Rating Type)
Current Rating
Rating Date
Current CreditWatch / Outlook
Current CreditWatch / Outlook Date
Issuer Credit Rating (Local Currency LT)
BBB+
Oct-27-2020
Positive
5/18/2023 10:51:02 AM
Issuer Credit Rating (Foreign Currency LT)
BBB+
Oct-27-2020
Positive
5/18/2023 10:51:02 AM


News Headlines
Date/Time
Headline
Source
Sep-12
Gilead Sciences Prices USD1 Billion in Public Offering of 5.250% Notes Due 2033
Marketline - Deals
Sep-11
Gilead Sciences Prices USD1 Billion in Public Offering of 5.550% Notes Due 2053
Marketline - Deals


Company Coverage
This company is not on any Coverage List.

Products
ACH-1095 (Future), AGEN1223 (Future), AGEN2373 (Future), AmBisome, Andecaliximab (Future), Atripla, Biktarvy, CART-ddBCMA (Future), Cayston, Cilofexor (Future), Cilofexor, Firsocostat and Selonsertib Combinations (Future), Cobicistat, Complera/Eviplera, DAR-312 (Future), Darunavir, Descovy, Descovy for PrEP, Domvanalimab + Durvalumab (Future), Domvanalimab + Zimberelimab (Future), Eleclazine (Future), Elipovimab (Future), Emtricitabine, Emtriva, Entospletinib (Future), Epclusa, Filgotinib (Future), Genvoya, Gilead COMPASS Initiative, GLPG-0555 (Future), GLPG-1205 (Future), GLPG-1690 (Future), GLPG-1972, GLPG-3312 (Future), GLPG-3667 (Future), GLPG-3970 (Future), GS 5885 (Future), GS-0976 (Future), GS-1423 (Future), GS-1811 (Future), GS-4059 (Future), GS-4224 (Future), GS-4774 (Future), GS-4875 (Future), GS-4997 (Future), GS-5245 (Future), GS-5734 (Future), GS-5745 (Future), GS-5816 (Future), GS-5829 (Future), GS-6207 (Future), GS-6637 (Future), GS-9131 (Future), GS-9669 (Future), GS-9674 (Future), GS-9688 (Future), GS-9722 (Future), GS-9820 (Future), GS-9857 (Future), GS-986 (Future), GS-9876 (Future), GS-9883 (Future), GS-9901 (Future), GS-9973 (Future), Harvoni, Hepcludex, Hepsera, Jyseleca, KITE-439 (Future), KITE-585, KITE-718 (Future), KTE-X19 (Future), Letairis, Lexiscan, Licensing of Tamiflu, Macugen, Magrolimab (Future), Magrolimab + Azacitidine (Future), NS4A Antagonists (Future), Odefsey, PGT121 (Future), Presatovir (Future), Ranexa, Selgantolimod (Future), Selonsertib (Future), SOF/VEL (Future), Sovaldi, STELLAR-3 (Future), Stribild, Sunlenca, Symtuza, Tamiflu, Tecartus, Tirabrutinib (Future), Trodelvy (Future), Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Vesatolimod (Future), Viread, Vitekta, Vosevi, Yescarta, Zydelig


Upcoming Events
Date/Time
Type
Oct-06-2023
Conferences
Oct-06-2023 1:45 PM (EDT)
Company Conference Presentations
Oct-10-2023
Conferences
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Reporting Owner(s)
Source
Form Type
Size
Sep-14-2023
Sep-14-2023
Gilead Sciences, Inc. (NasdaqGS:GILD)

SEC
8-K (1.01, 2.03, 8.01, 9.01)
722 KB
Sep-11-2023
-
Gilead Sciences, Inc. (NasdaqGS:GILD)

SEC
424B5
720 KB
Sep-07-2023
-
Gilead Sciences, Inc. (NasdaqGS:GILD)
Gilead Sciences, Inc. (NasdaqGS:GILD)
SEC
FWP
21 KB
Sep-07-2023
-
Gilead Sciences, Inc. (NasdaqGS:GILD)

SEC
424B5
669 KB
Aug-16-2023
Aug-16-2023
Gilead Sciences, Inc. (NasdaqGS:GILD)

SEC
8-K (7.01, 9.01)
9 MB
Aug-10-2023
Jun-30-2023
Gilead Sciences, Inc. (NasdaqGS:GILD)

Company Website
Preliminary Interim Report
10 MB
Aug-07-2023
-
Gilead Sciences, Inc. (NasdaqGS:GILD)

SEC
S-8
73 KB
Aug-04-2023
-
Gilead Sciences, Inc. (NasdaqGS:GILD)

SEC
S-3ASR
721 KB
Aug-04-2023
Jun-30-2023
Gilead Sciences, Inc. (NasdaqGS:GILD)

SEC
10-Q
12 MB
Aug-03-2023
Aug-03-2023
Gilead Sciences, Inc. (NasdaqGS:GILD)

SEC
8-K (2.02, 9.01)
2 MB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Dickinson, Andrew D. (Executive VP & CFO)
Sep-10-2023
Common Stock
(1,203)
(125,599)
Derivative Exercise and Sale
-
Form 4
-
Sep-10-2023
Common Stock
1,203
0
Derivative Exercise
-
Form 4
-
Sep-10-2023
Common Stock
(1,203)
(125,599)
Sale
-
Form 4
Dickinson, Andrew D. (Executive VP & CFO)
Sep-10-2023
Common Stock
1,416
0
Derivative Exercise and Retained Stock
1.32
Form 4
O'Day, Daniel P.  (Chairman & CEO)
Sep-10-2023
Common Stock
3,982
0
Derivative Exercise and Retained Stock
1.05
Form 4
O'Day, Daniel P.  (Chairman & CEO)
Sep-10-2023
Common Stock
(3,366)
(351,427)
Derivative Exercise and Sale
-
Form 4
-
Sep-10-2023
Common Stock
3,366
0
Derivative Exercise
-
Form 4
-
Sep-10-2023
Common Stock
(3,366)
(351,427)
Sale
-
Form 4
Parsey M.D., Ph.D., Merdad V. (Chief Medical Officer)
Sep-10-2023
Common Stock
(1,278)
(133,430)
Derivative Exercise and Sale
-
Form 4
-
Sep-10-2023
Common Stock
1,278
0
Derivative Exercise
-
Form 4
-
Sep-10-2023
Common Stock
(1,278)
(133,430)
Sale
-
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Colon, Grace E.
Chairman of the Board
650 574 3000
650 522 5853

O'Day, Daniel P. 
Chairman & CEO
650 574 3000
650 522 5853

Huff, Joel R.
Chairperson of Scientific Advisory Board
650 574 3000
650 522 5853
-
Kramer, Kelly A.
Independent Director
650 574 3000
650 522 5853

Lofton, Kevin E.
Lead Independent Director
650 574 3000
650 522 5853

Welters, Anthony 
Independent Director
650 574 3000
650 522 5853

Afdhal, Nezam H.
Member of Scientific Advisory Board
650 574 3000
650 522 5853

Anderson, Kenneth C.
Member of the Scientific Advisory Board
650 574 3000
650 522 5853

Barton, Jacqueline K.
Independent Director
650 574 3000
650 522 5853

Berg, Paul 
Member of Scientific Advisory Board
650 574 3000
650 522 5853
-
Bluestone, Jeffrey A.
Independent Director
650 574 3000
650 522 5853
jbluestone@sonomabio.com
Chisari, Francis V.
Member of the Scientific Advisory Board
650 574 3000
650 522 5853
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
O'Day, Daniel P. 
Chairman & CEO
650 574 3000
650 522 5853

Dickinson, Andrew D.
Executive VP & CFO
650 574 3000
650 522 5853

Patterson, Sandra 
Senior VP, Corporate Controller & Principal Accounting Officer
650 574 3000
650 522 5853

Ross, Jacquie 
Vice President of Investor Relations
(408) 656-8793
650 522 5853

Telman, Deborah H.
Executive VP of Corporate Affairs, General Counsel & Corporate Secretary
650 574 3000
650 522 5853

Mehra, Jyoti K.
Executive Vice President of Human Resources
650 574 3000
650 522 5853

Dorling, Janet 
Senior Vice President of Intercontinental Region & Global Patient Solutions
650 574 3000
650 522 5853

Ertl, Rudolf 
Senior Vice President of Commercial Operations of Australia, Canada, Europe
650 574 3000
650 522 5853

Fine, Bernard 
VP of Oncology & Franchise Head of Early Development
650 574 3000
650 522 5853

Grossman, William J.
Senior Vice President & Therapeutic Area Head of Gilead Oncology
650 574 3000
650 522 5853

Higgins, Linda Slanec
Senior Vice President of Research, Innovation & Portfolio
650 574 3000
650 522 5853

Ma, Stacey 
Executive VP of Pharmaceutical Development & Manufacturing
650 574 3000
650 522 5853

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
